Current Report Filing (8-k)
January 24 2018 - 2:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 23, 2018
RXi PHARMACEUTICALS
CORPORATION
(Exact name
of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36304
|
|
45-3215903
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code:
(508) 767-3861
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or
Rule 12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Check the appropriate box below if the Form
8-K
filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 8.01 Other Events.
On January 23, 2018, RXi Pharmaceuticals Corporation (the Company) received written notice (the Notification
Letter) from the Nasdaq Stock Market, LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The
Notification Letter was sent following the implementation of a
one-for-ten
reverse split of the Companys common stock (the Reverse Split), which became
effective on January 8, 2018. Additional information regarding the Reverse Split can be found in the Companys Current Report on Form
8-K
filed on January 5, 2018.
* * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION
|
|
|
|
|
Date: January 24, 2018
|
|
|
|
By:
|
|
/s/ Geert Cauwenbergh
|
|
|
|
|
|
|
|
|
Geert Cauwenbergh, Dr. Med. Sc.
Chief Executive Officer
|
3
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Sep 2023 to Sep 2024